Abstract: A method for making hepatocytes from extrahepatic somatic stem cells comprises: a) culturing somatic stem cells in a medium comprising hepatic growth factor to cause the stem cells to differentiate toward hepatocytes; b) culturing cells from a) in a medium comprising HGF and oncostatin M to facilitate the cell differentiation toward hepatocytes; and c) culturing cells from b) in a medium comprising oncostatin M to cause the differentiated cells to mature into hepatocytes, thereby producing a cell population that has morphological features of hepatocytes and at least four of the following characteristics: i) antibody-detectable expression of albumin; ii) real-time reverse transcriptase-polymerase chain reaction-detectable expression of ?-fetoprotein, HNF-1?, HNF-3?, HNF-4, HNF-6, ?1-antitrypsin, alkaline phosphatase, tryptophan 2,3-dioxygenase, tyrosine aminotransferase, cytochrome P450 family 2 subfamily E polypeptide 1, glutamine synthetase, and/or low density lipoprotein receptor; iii) urea secretion; iv) c
Type:
Grant
Filed:
June 23, 2009
Date of Patent:
November 22, 2011
Assignee:
National Yang-Ming University
Inventors:
Oscar Kuang-Sheng Lee, Tom Kwang-Chun Kuo
Abstract: An object of the present invention is to provide a composition for forming an environment friendly antifouling coating film that is unlikely to cause a hairline crack and like coating film defects even when immersed in seawater for a long time, and that prevents or inhibits attachment of slime.
Abstract: An object of the present invention is to provide a composition for forming an environment friendly antifouling coating film that can effectively exhibit an antifouling effect in seawater for a long period of time and furthermore exhibits a small temperature dependency of the coating film dissolving amount.
Abstract: Methods for determining a tumor in a human is disclosed. Also disclosed are methods for identifying adenocarcinoma, and methods for identifying squamous cell carcinoma in a human tumor sample. In addition, methods for predicting prognosis of metastasis and survival in a human having a tumor is disclosed.
Type:
Grant
Filed:
May 22, 2006
Date of Patent:
June 7, 2011
Assignee:
Advpharma Inc.
Inventors:
Yeh-Tze Chou, Harn-Jing Terng, Hsuan-Yu Chen, Sung-Liang Yu, Jeremy J. W. Chen, Pan-Chyr Yang
Abstract: A method for precipitating casein from a suspension comprising milk is disclosed. The method includes the following steps: adding a phosphate solution to a suspension; mixing the phosphate solution with the suspension to form a mixture having a phosphate concentration greater or equal to 40 mM; freezing the mixture having a phosphate concentration greater or equal to 40 mM to obtain a frozen mixture; and thawing the frozen mixture to obtain casein-containing aggregates in the mixture, in which the phosphate solution is buffered at a pH value of no less than 4.4.
Abstract: The present invention relates to a method for providing bactericide or bacteriostatic, especially for treating disease due to bacterial infection. The method comprising administering a patient in need of such treatment a therapeutically effective amount of a compound of dextromethorphan or naloxone or a pharmaceutically acceptable salt or an analog thereof. The compound is applied to skin or mucosal surface of the patient. The invention also relates to a method of treating inflammation caused by suppressing secretion of TNF-?, IL-6, or MCP-1 from macrophage comprising administering a patient in need of such treatment a therapeutically effective amount of NADPH oxidase inhibitor.
Abstract: The present invention relates to use of polysaccharides obtained from Dendrobium for treating an allergic disease or for reducing airway-remodeling caused by inflammation.
Abstract: The present invention relates to isolated influenza virus strains suitable for increased vaccine production for mammals. The influenza virus strains contain at least one modified influenza protein that results in increased production of the influenza virus from a mammalian host cell, such as a vero cell. The present invention also relates to the vaccines produced from the influenza virus strains. The present invention further relates to isolated modified influenza proteins and isolated nucleic acid molecules that encode for the modified influenza proteins.
Abstract: The invention relates to a composition for promoting angiogenesis, for controlling DNA synthesis of a cell, and for controlling chemotactic motility of a cell. The invention also relates to a method for treating ischemia diseases.
Abstract: Expression system for enhancing solubility and immunogenicity of recombinant proteins. The expression system includes a protein expression vector that contains a chimeric gene encoding a chimeric protein comprising: (a) a first polypeptidyl fragment at the N-terminal end of the chimeric protein, containing a protein transduction domain (PTD), or a fragment thereof, having HIV Tat PTD activity; (b) a second polypeptidyl fragment at the C-terminal end of the first polypeptidyl fragment, containing a J-domain, or a fragment thereof, having heat shock protein 70 (Hsp70)-interacting activity; and (c) a third polypeptidyl fragment at the C-terminal end of the second polypeptidyl fragment, containing a target protein or polypeptide.
Type:
Grant
Filed:
March 18, 2009
Date of Patent:
July 20, 2010
Assignees:
Stresspro Biomedicine Incorporation, Animal Technology Institute Taiwan
Inventors:
Ming-Yu Chen, Chin-Kai Chuang, Yu-Hsyu Su, Chiu-Ting Fan, Jung-Chuan Yu, Wen-Chuan Lee
Abstract: The present invention discloses a method for treating cancer by using hCRMP1 and/or active fragments thereof, as well as the active fragments of hCRMP1 that are capable of inhibiting cell proliferation, invasive activity, and metastasis of cancer. The method can also be used prior to, or in combination with, the administration a chemotherapy agent. A vector capable of expressing an hCRMP1, a variant of hCRMP1, a fragment of hCRMP1 or a variant of a fragment of hCRMP1 is also disclosed.
Type:
Grant
Filed:
March 21, 2008
Date of Patent:
June 22, 2010
Assignee:
Advpharma Inc.
Inventors:
Harn-Jing Terng, Yi-Jen Lee, Woan-Jen Lee
Abstract: The present invention provides carbohydrate encapsulated nanoparticles. In particular, the present invention provides metallic nanoparticles (e.g. gold nanoparticles) that are encapsulated in biologically important carbohydrate molecules, such as sugars, sugar derivatives, P-blood group antigens and analogues thereof. The present invention also provides methods of employing these carbohydrate encapsulated nanoparticles in diagnostic and therapeutic applications.
Type:
Grant
Filed:
February 19, 2004
Date of Patent:
April 13, 2010
Assignees:
Academia Sinica, National Taiwan University, National Taiwan Normal University
Abstract: A genetically modified zebrafish embryo, comprising a HBNF cDNA or a NGF cDNA or a GDNF cDNA together with a cDNA encoding green fluorescent protein (GFP) so as to induce neurite outgrowth during said zebrafish embryonic development, and a method of using such genetically modified zebrafish embryo to identify a therapeutic agent are disclosed.
Abstract: This invention provides a transcription unit which is isolated from the upstream nucleic acid sequence of the collapsing response mediator protein-1 (CRMP-1) gene, an invasion-suppressor gene. The transcription unit contains a nucleic acid regulatory sequence which demonstrates promoter and/or regulatory activities (such as providing a transcription factor binding site) to enhance the expression of the CRMP-1 and/or a reporter protein. The invention also provides a DNA construct containing this transcription unit which can be transfected into a host cell. Additionally, the invention provides methods to enhance the expression of CRMP-1 and/or the reporter protein. The over-expression of CRMP-1 in a cancer cell can inhibit the metastasis of the cancer cell.
Type:
Grant
Filed:
April 19, 2007
Date of Patent:
February 2, 2010
Assignee:
Advpharma Inc.
Inventors:
Pan-Chyr Yang, Tse-Ming Hong, Jeremy J. W. Chen, Cheng-Chung Wu, Jin-Yuan Shin, Yi-Jen Lee
Abstract: Orthogonally protected disaccharide building blocks for synthesis of heparin saccharide are disclosed. The disaccharide building block has a formula (I), in which L is a leaving group, P1, P2, P3 and P4 are different, and of them P1 is an ester-type protecting group, P2 is a hydroxyl protecting group that could be oxidized to a carboxylic acid, P3 is a hydroxyl protecting group, and P4 is a hydroxyl protecting group which allows chemoselective deprotection with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ). Acting as an elongation unit, the disaccharide building block of formula (I) may react with a starting unit of formula (II) to synthesize a heparin saccharide of desired size.
Type:
Grant
Filed:
January 7, 2008
Date of Patent:
February 2, 2010
Assignee:
Academia Sinica
Inventors:
Shang-Cheng Hung, Jing-Chyi Lee, Xin-An Lu
Abstract: The present invention relates to the novel protein Insulin-Responsive DNA Binding Protein-1 (IRDBP-1) and nucleotide sequences that encode it. IRDBP-1 binds to nucleic acid regions of genes that respond when cells are exposed to insulin. IRDBP-1 regulates genes important in mediating the insulin response in mammals and in regulating conditions such as diabetes, obesity, insulin-resistant syndrome and cell proliferative disorders. The present invention provides nucleic acids useful as probes for detecting nucleic acids encoding regions of the IRDBP-1 protein.
Abstract: The present invention relates to a super-antigen fusion protein, comprising: a peptide fragment whose sequence corresponds to a partial SARS E2 spike protein; and a translocating peptide fragment for transporting a protein into a cell and translocating the protein in cytosol; wherein, the amino acid sequence of the peptide fragment corresponding to the partial SARS E2 spike protein includes SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3 or SEQ ID NO. 4. The present invention further relates to DNA sequences corresponding to the partial SARS E2 spike protein includes SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, or SEQ ID NO. 8; wherein the DNA sequences are able to express specific proteins in an E. Coli expression system.
Abstract: Fusion antigen used as vaccine. The invention relates to a fusion antigen specific for a target cell. The fusion antigen contains a ligand moiety, a Pseudomonas exotoxin A translocation domain II, an antigenic moiety, and a carboxyl terminal moiety. The ligand moiety is capable of reacting, recognizing or binding to receptors on the target cell. The carboxyl terminal moiety permits retention and processing of the fusion antigen in the endoplasmic reticulum (ER) membrane of the target cell. Pharmaceutical compositions and methods of inducing an immune response using the same are also disclosed.
Abstract: Orthogonally protected disaccharide building blocks for synthesis of heparin oligosaccharide. The disaccharide building block has a formula (I), in which L is a leaving group, P1, P2, P3 and are different, and of them P1 is an ester-type protecting group, P2 is a hydroxyl protecting group that could be oxidized to a carboxylic acid, P3 is a hydroxyl protecting group, and P4 is a hydroxyl protecting group which allows chemoslective deprotection with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ). Acting as an elongation unit, the disaccharide building block of formula (I) may react with a starting unit of formula (II) to synthesize a heparin oligosaccharide.
Type:
Grant
Filed:
July 20, 2005
Date of Patent:
September 1, 2009
Assignee:
Academia Sinica
Inventors:
Shang-Cheng Hung, Jing-Chyi Lee, Xin-An Lu
Abstract: The present invention relates to the novel protein Insulin-Responsive DNA Binding Protein-1 (IRDBP-1) and nucleotide sequences that encode it. IRDBP-1 binds to nucleic acid regions of genes that respond when cells are exposed to insulin. IRDBP-1 regulates genes important in mediating the insulin response in mammals and in regulating conditions such as diabetes, obesity, insulin-resistant syndrome and cell proliferative disorders. The present invention provides nucleic acids useful as probes for detecting nucleic acids encoding regions of the IRDBP-1 protein.